Navigation Links
Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market

SEATTLE, April 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that on April 2, 2009, CTI received notice from The NASDAQ Stock Market ("NASDAQ") indicating that the company has evidenced full compliance with all applicable requirements for continued listing on The NASDAQ Capital Market. The notice followed CTI's compliance with the minimum $35 million market value of listed securities requirement for a minimum of ten consecutive trading days, as required by Marketplace Rule 4310(c)(3). As of April 1, 2009, the company's market capitalization was $113,287,573.

"We are pleased to have regained compliance with The NASDAQ Capital Market listing standards as the result of the increase in our share price, which we believe is attributable to the progress we continue to make in our drug development programs," said James A. Bianco, M.D., CEO of Cell Therapeutics. "We look forward to adding greater shareholder value through our submission of a New Drug Application (NDA) for pixantrone for aggressive relapse non-Hodgkin's lymphoma in the second quarter of 2009 and potential approval this year, in addition to other strategic business initiatives we are currently pursuing."

As disclosed on September 6, 2008 and October 10, 2008, the company was previously notified by NASDAQ regarding its non-compliance with the $50 million market value of listed securities requirement for continued listing on The NASDAQ Global Market. At the company's request, on January 6, 2009, the NASDAQ Listing Qualifications Panel determined to transfer the listing of the company's common stock from The NASDAQ Global Market to The NASDAQ Capital Market, subject to the company demonstrating compliance with all applicable requirements for continued listing on The NASDAQ Capital Market, which deadline was extended to April 6, 2009. The matter is now closed.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These risks and uncertainties include, without limitation, the Company's ability to sustain compliance with the NASDAQ Capital Market's continued listing requirements, as well as other risks and uncertainties that could affect the Company's business operations and the development of the Company's products including the Company's ability to raise additional capital to fund its continued operations, risks associated with preclinical and clinical developments in the biopharmaceutical industry in general including, without limitation ,the Company's ability to submit an NDA in the first half of 2009 for pixantrone and gain approval in 2009, the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling pixantrone. You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T : 206.272.4347
    F : 206.272.4434

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
2. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
3. Arno Therapeutics Reports 2008 Year-End Financial Results
4. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
5. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
6. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
7. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
8. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
9. Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure
10. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
11. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
Post Your Comments:
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
Breaking Biology News(10 mins):